INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive genetic condition caused by mutations in the gene encoding the CF transmembrane regulator (CFTR) that affects around 10 000 people in the UK. 1, 2 CF is a multisystem condition 1 but lungs are the main organ affected, with CFTR dysfunction causing abnormal airway surface liquid. 1, 3 People with CF are particularly susceptible to infection causing acute deterioration in lung health (i.e. pulmonary exacerbations), which leads to progressive lung damage and eventually respiratory failure. 4 An important treatment option in CF is preventative inhaled therapies consisting of mucolytics and antibiotics, which have proven efficacy in reducing the frequency of exacerbations. 5 , 6 The effectiveness of these treatments is however limited by a real-world medication adherence rates of 35-50%. 7, 8 Acute treatment of pulmonary exacerbations has relatively limited research evidence. 9 However, the importance of intravenous (i. v.) antibiotics in managing CF is indisputable-CF centres that use less antibiotics or have higher threshold for initiating i.v. in the face of an exacerbation were associated with people having lower lung function. 10, 11 Indeed, i.v. antibiotics are recommended in all the major CF guidelines to treat exacerbations. [12] [13] [14] [15] Understanding the clinical characteristics associated with i.v. antibiotics use is clinically important as it can provide insight into the care that people with CF need and the resources that are required for CF care. Exacerbation is also an important end point in CF clinical trials, 16 and clinical factors associated with exacerbation could have implications for trial design.
A recent US CF Foundation Patient Registry (US CFFPR) data analysis has found that the frequency of prior-year i.v.-treated exacerbations is strongly associated with the frequency of future-year i.v.-treated exacerbations, 17 even after adjustment for the other case-mix factors, for example lung function. [17] [18] [19] We analysed the 2013-2014 UK CF registry data to test whether the hypothesis that prior-year i.v. use is associated with future-year i.v. use, is also generalizable to the UK CF population.
METHODS
This is a cross-sectional analysis using the UK CF registry data for 2013-2014 from 28 UK adult CF centres. National Health Service (NHS) research ethics approval (Huntingdon Research Ethics Committee 07/Q0104/2) was granted for the UK CF Registry. Under the terms of the NHS ethics approval, the UK CF Trust steering committee approved this study.
People with lung transplantation and those on ivacaftor were excluded as both treatments have transformative effects on health outcomes, 20, 21 such that their exacerbation rates and forced expiratory volume in 1 s (FEV 1 ) no longer represent that of a typical adult with CF.
Data
The following data were obtained • Annual total i.v. antibiotic days (in number of days).
Data were collected from people aged ≥16 years during annual reviews from January 2013 to December 2014. Since prior-year i.v. use was a covariate in the analysis, i.v. use data for 2012 were also obtained.
Number of days on i.v. antibiotic, instead of number of i.v. courses, was chosen for analysis since it captures information on the cumulative i.v. antibiotic exposure to treat pulmonary exacerbations over a 1-year period (not all i.v. courses are of the same duration). 25 
Statistical analysis
Analyses were performed using SPSS v22 (IBM Corp, Armonk, NY, USA). Data for 2013 and 2014 were analysed separately to determine the consistency of any observations. The analysis consisted of two stages. First, logistic regression was performed to identify the order of the strength of association between the demographic and clinical variables with the current-year i.v. use. Based on these results, the study sample was divided into clinically meaningful subgroups using analysis similar to tree-based method 26 for comparison of current-year i.v. use between the subgroups.
Logistic regression was performed using current-year i.v. days (≤14 days vs >14 days) as the dependent variable. 14-Day was selected as the cut-off since mean and median duration of each i.v. course in 2013 and 2014 was 14 days. The duration of a 'standard' i.v. course to treat an exacerbation is usually 14 days, 12, 15 and people with ≥2 exacerbations per year (i.e. time between exacerbation <6 months 17 ) have the most rapid FEV 1 decline. 27 Age, gender, CF centre (as a categorical variable), pancreatic status, CF-related diabetes, intermittent P. aeruginosa (yes/no), chronic P. aeruginosa (yes/no), BMI, %FEV 1 and prior-year i.v. days (as a continuous variable) were the covariates. For this procedure, forward stepwise conditional analysis (probability for entry 0.05; probability for removal 0.10) was performed in a binary logistic regression model. The procedure began by identifying the covariate that was most strongly associated with current-year i.v. use. The next strongest associated covariate was then selected after controlling for the first covariate. This continued until no further statistically significant covariates can be added to the model. Stepwise regression allows a relatively parsimonious model to be built even when several correlated covariates are present, 28, 29 but it is essentially an exploratory analysis because it can lead to inflated Type I errors. 30, 31 Therefore, the results from the stepwise logistic regression were subjected to a further analysis similar to tree-based method to test the hypothesis that prioryear i.v. use is associated with future-year i.v. use. Tree-based method is an efficient approach to understand the impact of risk factors for a condition where many potential confounders exist. 24 For this analysis, the covariate most strongly associated with currentyear i.v. use as identified by stepwise logistic regression was used for the first 'layer' division of the study sample. Then, a further 'layer' of division for each generated subgroup was carried out using the next strongest associated covariate, and so on. For continuous covariates, clinical meaningful cut-off points were used to divide the cohort instead of data-driven optimal cut-off points to avoid overfitting. 32 For %FEV 1 , internationally accepted categories (<40%, 40-69.9% and ≥70%) were used as these categories are also applicable to the UK CF registry data. 33 Prior-year i.v. days were categorized into ≤14 days versus >14 days, similar to current-year i. v. days. The current-year i.v. days, as a continuous variable, were compared between subgroups at each 'layer' of the division using Mann-Whitney test or Jonckheere-Terpstra test depending on the number of subgroups, due to the non-normal distribution of i.v. days. Jonckheere-Terpstra test is a generalization of the Mann-Whitney test for more than two ordered groups.
The analyses included those without any pulmonary exacerbations needing i.v. antibiotics (n = 1847, 43.3% of the sample for 2013; n = 2037, 43.9% of the sample for 2014) to obtain a more representative understanding of the adult CF population in the UK. P-value <0.05 was considered to be statistically significant. Complete case approach was used as the extent of missing data (summarized in Fig. 1 ) was small. There were >1500 people with >14 days i.v. days for each year, which is more than adequate power for nine covariates in a binary logistic regression model. 34 The study sample was also considerably larger than previous studies looking at factors associated with exacerbations 18, 19 (except the recent US CFFPR analysis), which should allow adequate power for hypothesis testing between the different subgroups.
RESULTS
A total of 4269 adults were included in the analysis for 2013 and 4644 for 2014, with 4874 study subjects in total across both years. In total, 103 453 i.v. days were used in 2013 and 111 981 i.v. days were used in 2014. Figure 1 summarizes the numbers of adults excluded and missing data. Baseline demographics stratified according to previous i.v. days was summarized in Table 1 . Those with previous-year i.v. use >14 days had lower FEV 1 and higher current-year i.v. use for both 2013 and 2014.
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Therefore, the cohort was divided into two groups based on prior-year i.v. use (≤14 days and >14 days) Figure 1 Summary of the number of adults included in the analyses and details regarding missing data.
† Cystic fibrosis (CF)-related diabetes (CFRD) data are collected by the UK CF registry with only a check-box for 'CFRD present'. Therefore, if data are not available, it is assumed the person has no CFRD. It is therefore difficult to distinguish missing data from 'no CFRD' and hence missing data = 0. ‡ Data for pancreatic replacement therapy (PERT) use were obtained. People on PERT were considered 'pancreatic insufficient'. People not on PERT were considered 'pancreatic sufficient'. PERT use documented as 'unknown' is considered as missing data.
and then each group is further divided into three subgroups based on %FEV 1 (<40%, 40-69.9% and ≥70%) to generate six subgroups in total. The results of this analysis are summarized in Figures 2 and 3 .
Current-year i.v. use was clearly different between all the subgroups and the results were consistent for both 2013 and 2014. Adults with high prior-year i.v. use (i.e. >14 days) continued to require high levels of i.v., even if they have good FEV 1 . Indeed, adults with high prior-year i.v. use and FEV 1 ≥ 70% had higher currentyear i.v. days compared to adults with low prior-year i. v. use and FEV 1 < 40% for both 2013 (28 days, interquartile range (IQR): 11-41 days vs 14 days, IQR: 0-28 days; P < 0.001) and 2014 (22 days, IQR: 10-42 days vs 14 days, IQR: 0-35 days; P = 0.003).
The clinical subgroups could be generated using different cut-off points for prior-year i.v. use but the results remained similar (see Appendix S4, Supplementary Information, for these sensitivity analyses).
DISCUSSION
This study found that adults with high prior-year i.v. use (>14 days) and low FEV 1 (<40%) required the most i.v. among the six different clinical subgroups. In 2013, this group consisted 13.4% of the population but consumed 38.7% of i.v. days. Prior-year i.v. use was a much stronger predictor of current-year i.v. use compared to FEV 1 , such that those with high prior-year i.v. use and high FEV 1 (≥70%) still used more i.v. therapies compared to those with low prior-year i.v. use (≤14 days) and low FEV 1 . The 2013 results were consistent with 2014 results, suggesting that chance is extremely unlikely to explain these results.
The finding that prior-year i.v. use was the strongest independent predictor of current-year i.v. use is consistent with the recent US CFFPR analysis. 17 Whilst we acknowledge the limitations of retrospective observational registry-based analyses that have been previously discussed, 17 ,35 the consistency and magnitude of the finding would suggest a genuine signal. The implications of this finding for clinical trials had also been discussed in detail-stratification of subject randomization by prior-year i.v. use would be helpful to balance the baseline risk of pulmonary exacerbation. In fact, our randomized control trial to evaluate a complex self-care intervention used this strategy for randomization.
36
This finding also has other important clinical implications and could suggest possible differences in management strategies. Management of CF can be broadly dichotomized into 'rescue' therapy with i.v. antibiotics to treat pulmonary exacerbations and 'prevention' with inhaled therapies to minimize the risk of exacerbations. 37 Whilst exacerbations may be stochastic events, the frequency and severity of exacerbations over a given period in a person with CF will be influenced by their clinical characteristics, environmental exposures and medical treatments. 38 Given the efficacy of preventative inhaled therapies in reducing the frequency of exacerbations, 5,6 a possible explanation for high i.v. use would be the reliance on rescue therapies to compensate for insufficient utilization of preventative therapies.
Prior-year i.v. use could also guide clinical strategy in managing CF. Insufficient utilization of preventative therapy could be due to low adherence, as median adherence with inhaled therapies in the real world is only 35-50%. 7, 8, 39 Therefore, it is important to obtain objective adherence data wherever possible when assessing an adult with CF, especially if i.v. use is disproportionately high in relation to FEV 1 .
If objective nebulizer adherence is satisfactory, another cause for insufficient utilization of preventative therapy to consider is 'therapeutic inertia'. Therapeutic inertia refers to the under-prescription of efficacious treatments. 40 In CF, the prescription of inhaled therapies have increased since mid 1990s. [41] [42] [43] Adherence rates to international prescribing guidelines now exceed 90% for some specialist CF centres. 44 If i.v. requirement is still disproportionately high but objective adherence is high and no obvious complications are found, escalation of preventative therapies should be considered. An example would be the initiation of inhaled antibiotic treatment for someone who is only on inhaled mucolytics. The detection of P. aeruginosa infection would typically prompt the prescription of inhaled antibiotics. However, there may be merit in using long-term inhaled antibiotics, even when P. aeruginosa is not detected, if there is a history of frequent exacerbations. 45 This is a strategy that has some evidence of success in non-CF bronchiectasis. 46 Our finding highlights potential limitations of FEV 1 as a marker of lung health. Low FEV 1 is a known poor prognostic marker in CF and is strongly associated with mortality.
47,48 FEV 1 trend is therefore a commonly used primary end point in CF clinical trials and an important parameter measured during annual reviews as a marker of lung health for adults with CF. 16, 49 However, as the health of people with CF improved over time, the sensitivity of FEV 1 as a marker of lung health decreases. 50 This study found a group of people with high i.v. use year on year, yet who maintained relatively good lung function (FEV 1 > 70%). It may be possible to initially fend off FEV 1 decline despite frequent exacerbations by simply relying on prompt and aggressive rescue i.v. treatments. Such strategy is likely to result in wild fluctuations of FEV 1 , with high FEV 1 post i.v. treatment not sustained due to lack of preventative treatments. A trend of declining FEV 1 tends to be predated by increased FEV 1 variability 51 ; hence, FEV 1 variability is a more sensitive marker of lung health. There is increasing evidence regarding the prognostic impact of FEV 1 variability, 51 ,52 but we were not able to study the correlation between FEV 1 variability and i.v. use as the UK CF registry does not routinely collect encounter-based FEV 1 data.
In conclusion, exacerbations as indicated by i.v. use are clinically important events in CF with long-term impact on morbidity and mortality. Prevention of exacerbations is a priority due to the risk of FEV 1 decline and lung damage even with intensive i.v. antibiotics, hence the importance of understanding the predictors of frequent exacerbations. This UK CF registry analysis used i.v. days as a marker of the frequency and severity of exacerbations, and found that currentyear i.v. use is most strongly associated with prior-year i.v. use. A recent US CFFPR data analysis also found similar results. 17 That means those with history of frequent exacerbations continue to remain most at risk for future exacerbations, even with good FEV 1 . Inadequate utilization of preventative inhaled therapies may be one of the reasons for this reliance on rescue therapies. Therefore, high i.v. use should prompt clinicians to assess both the adherence rate and the prescribed inhaled therapies regime.
